Summary The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers -carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) -and a new serum tumour marker, tissue polypeptide specific antigen (TPS) , in the diagnosis of pancreatic cancer. The serum values were measured in a prospective series of patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a cancer of the papilla of Vater in this series. Our results showed that CA 50 (P<0.001) and TPA (P<0.01) were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242 (P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not (P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DS1) was developed. The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (-1.21). The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of 82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and TPA.
The production of monoclonal antibodies by hybridoma technology (Kohler & Milstein, 1975) has been a new beginning for the development of monoclonal antibodies to cancer. Tumour markers are applied clinically in the following ways: (1) to study the biology of cancer, (2) to aid in diagnosis of cancer, (3) to determine the prognosis of cancer and (4) to monitor the progress of patients with cancer.
In the diagnosis of human pancreatic cancer, several serum tumour-associated antigens have been studied intensively during the past decade (Haglund et al., 1987; Benini et al., 1988; Masson et al., 1990; Haglund et al., 1992; Tian et al., 1992) . In many studies large numbers of markers have been tested separately, mostly by single-factor analyses, with varying cut-off levels and in varying patient populations. For these reasons, evaluation of these studies is often difficult. Furthermore, according to many previous studies, it is obvious that the combined use of many similar marker tests is unreasonable from the clinical or economic point of view (Haglund et al., 1986; Benini et al., 1988; Pasanen et al., 1992 (Albert, 1982; Feinstein, 1985) . The cut-off levels were determined by performing a receiver operating characteristic (ROC) curve analysis for each marker test (Feinstein, 1985; Pasanen et al., 1993) . A multivariate stepwise discriminant analysis was carried out to study the independent diagnostic value of each marker test and to find the best combination of the different tests in predicting pancreatic malignancy (Goldberg & Ellis, 1978) .
Results
The serum values (median, interquartile range) of CEA, CA 50, CA 242, TPA and TPS in pancreatic cancer and in patients with benign hepatopancreatobiliary diseases are shown in Table I . The differences between these patient groups were highly significant for all marker tests (Table  I) .
The diagnostic accuracy of each marker test in pancreatic cancer is summarised in In a multivariate stepwise discriminant analysis, the CA 50 test showed the strongest (P<0.001) diagnostic value. Also, the TPA test proved to be a significant (P<0.01) independent predictor of pancreatic malignancy, while the TPS and CA 242 tests showed only marginally significant independent diagnostic value (P = 0.07 and P = 0.08 respectively; Table  III ). In order to sum up the contributions of different markers, a diagnostic score (DS1) was developed. The dis- Cut-off levels: CEA, 4.1 ng ml-'; CA 50, 137 U ml'; CA 242, 21 U ml'; TPA, 320 Ul-; TPS, 630UI-'. (Table II) . When the combination of the two best markers, i.e. that of CA 50 and TPA, was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. The post-test probability of malignant disease for DS2 was 38%, and the LR + was 3.4 and LR -0.63 (Table II) . Correlations between the marker tests are shown in Table  IV . In the patients with pancreatic cancer, there was a significant positive correlation between CEA and TPS (r = 0.49, P = 0.01), and between CA 50 and CA 242 (r = 0.98, P = 0.0001). All other markers showed nonsignificant correlations (Table IV) . In benign hepatopancreatobiliary diseases, TPA showed a significant positive correlation with all other markers, and there was also a significant positive correlation between CA 50 and CA 242 (r = 0.89, P = 0.0001, Table IV ).
Discussion
In order to gain more insight into the complex issue of the use of serum tumour markers in the diagnosis of pancreatic cancer, we have recently stressed the usefulness of ROC curve analysis (Pasanen et al., 1993) . In many medical studies the use of discriminant analysis has also been seen to be of great potential for simultaneous testing of the real independent value of various diagnostic tests (Goldberg & Ellis, 1978) . In this particular study, therefore, we decided to use both these methods to clarify the diagnostic value and role of the five current serum tumour markers in the diagnosis of pancreatic cancer.
The results of the current study showed that all marker tests except TPS reached considerably similar and high efficiencies (80-83%, Table II ). This confirms previous data for CEA, CA 50, and CA 242, whereas few data are available in the literature on the utility of serum TPA assays, and there are no data regarding TPS assay in the diagnosis of pancreatic cancer. TPA is a protein produced by rapidly growing tissues (Bjorklund & Bjorklund, 1957; Bjorklund, 1980) . Since the release of this antigen is a function of cell division, it differs from many other tumour marker tests by indicating the tumour proliferative rate rather than the tumour burden (Bjorklund & Bjorklund, 1983) . The diagnostic value of TPA has been reported to be slightly inferior to that of CA 50 (Benini et al., 1988) , but a very high sensitivity (96.4%) has also been reported (Panucci et al., 1985) . In our study, the sensitivity of TPA was clearly lower (52%) than that of CEA, CA 50 and CA 242, but the specificity of TPA was highest (85%) of all. However, at high specificity levels (>0.90) TPA showed unacceptably low sensitivities, while the CA 242 test performed best. Nevertheless, in the multivariate analysis, the TPA test proved an independent predictor of pancreatic malignancy in addition to the CA 50 test. Thus, our results speak for some clinical utility of TPA despite its considerably low sensitivity. TPS is the M3-specific epitope of TPA (Bjorklund, 1980; Bjorklund & Bjorklund, 1983) , and in theory it might show higher specificity in patients with pancreatic cancer. In the present multivariate analysis, TPS showed marginally independent diagnostic value, but our results showed clearly that the diagnostic value of TPS is inferior to that of all other markers, even though its specificity, PV and efficiency were very high.
According to the present analysis, the value of the computer-aided scoring system based on multiple tests seems to be limited, since despite the considerable improvement in specificity the sensitivity remained low (Table II) . The multivariate analysis revealed that only the CA 50 and TPA tests showed significant independent diagnostic value, and that the diagnostic score of these two markers as such was equal to that of multiple tests. Some explanation for this can be sought by the correlation analysis. Our results showed that the CA 50 and CA 242 tests had a high positive correlation in both the patients with pancreatic cancer and those with benign disorders (Table IV) , supporting the similarity of these tests, a result that was to be expected on the basis of previous studies (Haglund et al., 1989; Kuusela et al., 1991 (Table  IV) , which were not proliferative processes, and it fits poorly with the fact that TPA is a protein produced by rapidly growing tissues. No good explanation for this can be given, but elevated TPA levels caused by hepatitis and liver cirrhosis have been similarly reported in previous studies (Bjorklund, 1980; Andriulli, 1985) . Interestingly, there was a significant positive correlation between the CEA and TPS concentration in the patients with pancreatic cancer, and between CEA and TPA in the patients with benign hepatopancreatobiliary diseases (Table IV) .
In conclusion, the further advantage gained by a computer-aided scoring system based on multiple tests seems to be limited, and the use of several marker tests with similar antigenicity gives only little further benefit, whereas combinations of different kinds of markers may give more fruitful additional information. The best combination of these serum tumour marker tests in predicting pancreatic malignancy is the combination of CA 50 and TPA.
